Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

被引：0

作者：

Mara Persano

Margherita Rimini

Toshifumi Tada

Goki Suda

Shigeo Shimose

Masatoshi Kudo

Jaekyung Cheon

Fabian Finkelmeier

Ho Yeong Lim

Lorenza Rimassa

José Presa

Gianluca Masi

Changhoon Yoo

Sara Lonardi

Francesco Tovoli

Takashi Kumada

Naoya Sakamoto

Hideki Iwamoto

Tomoko Aoki

Hong Jae Chon

Vera Himmelsbach

Tiziana Pressiani

Takumi Kawaguchi

Margarida Montes

Caterina Vivaldi

Caterina Soldà

Fabio Piscaglia

Atsushi Hiraoka

Takuya Sho

Takashi Niizeki

Naoshi Nishida

Christoph Steup

Massimo Iavarone

Giovanni Di Costanzo

Fabio Marra

Mario Scartozzi

Emiliano Tamburini

Giuseppe Cabibbo

Francesco Giuseppe Foschi

Marianna Silletta

Masashi Hirooka

Kazuya Kariyama

Joji Tani

Masanori Atsukawa

Koichi Takaguchi

Ei Itobayashi

Shinya Fukunishi

Kunihiko Tsuji

Toru Ishikawa

Kazuto Tajiri

机构：

[1] University Hospital of Cagliari,Medical Oncology

[2] IRCCS San Raffaele Hospital,Department of Medical Oncology

[3] Japanese Red Cross Himeji Hospital,Department of Internal Medicine

[4] Hokkaido University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[5] Kurume University School of Medicine,Division of Gastroenterology, Department of Medicine

[6] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[7] CHA University School of Medicine,Department of Medical Oncology, CHA Bundang Medical Center

[8] University Hospital Frankfurt,Department of Internal Medicine 1

[9] Goethe University,Department of Medicine, Samsung Medical Center, School of Medicine

[10] Sungkyunkwan University,Department of Biomedical Sciences

[11] Humanitas University,Unit of Medical Oncology 2

[12] Humanitas Cancer Center,Department of Translational Research and New Technologies in Medicine and Surgery

[13] IRCCS Humanitas Research Hospital,Department of Oncology, ASAN Medical Center

[14] Liver Unit-CHTMAD,Oncology Unit 1

[15] University Hospital of Pisa,Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases

[16] University of Pisa,Department of Nursing

[17] University of Ulsan College of Medicine,Gastroenterology Center

[18] Veneto Institute of Oncology IOV-IRCCS,Division of Gastroenterology and Hepatology

[19] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Dipartimento di Medicina Sperimentale e Clinica

[20] Gifu Kyoritsu University,Department of Oncology and Palliative Care, Cardinale G Panico

[21] Ehime Prefectural Central Hospital,Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE

[22] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano,Department of Internal Medicine

[23] Department of Hepatology,Division of Medical Oncology

[24] Università di Firenze,Department of Gastroenterology and Metabology

[25] Tricase City Hospital,Department of Gastroenterology

[26] University of Palermo,Department of Gastroenterology and Hepatology

[27] Ospedale per gli Infermi di Faenza,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[28] Policlinico Universitario Campus Bio-Medico,Department of Hepatology

[29] Ehime University Graduate School of Medicine,Department of Gastroenterology

[30] Okayama City Hospital,Department of Gastroenterology

[31] Kagawa University,Center of Gastroenterology

[32] Nippon Medical School,Department of Gastroenterology

[33] Kagawa Prefectural Central Hospital,Department of Gastroenterology

[34] Asahi General Hospital,Hepato

[35] Osaka Medical and Pharmaceutical University,biliary Center

[36] Teine Keijinkai Hospital,Department of Gastroenterology and Hepatology

[37] Saiseikai Niigata Hospital,Department of Gastroenterology

[38] Toyama University Hospital,Division of Gastroenterology and Hepatology, Department of Internal medicine

[39] Japanese Red Cross Matsuyama Hospital,Department of Gastroenterology

[40] Ogaki Municipal Hospital,Department of Clinical Research

[41] Japanese Red Cross Takamatsu Hospital,Division of Gastroenterology and Hepatology

[42] Hyogo Medical University,Department of Hepatology

[43] Gunma Saiseikai Maebashi Hospital,Department of Surgery

[44] National Hospital Organization Takasaki General Medical Center,Department of Gastroenterology

[45] Otakanomori Hospital,Drug Development Unit

[46] Hamamatsu University School of Medicine,Department of Oncology

[47] Kansai Medical University,undefined

[48] National Hospital Organization Takasaki General Medical Center,undefined

[49] Sarah Cannon Research Institute UK,undefined

[50] IRCCS San Raffaele Scientific Institute Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Advanced HCC; Atezolizumab plus bevacizumab; First-line therapy; Lenvatinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：5591 / 5602

页数：11

共 50 条

[1] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Rimassa, Lorenza
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Pressiani, Tiziana
Kawaguchi, Takumi
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Piscaglia, Fabio
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Scartozzi, Mario
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5591 - 5602
[2] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Persano, M.
Piscaglia, F.
Scartozzi, M.
Cascinu, S.
Rimini, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
[3] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
Rossari, Federico
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Yoo, Changhoon
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Bergamo, Francesca
Amadeo, Elisabeth
Vitiello, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Iavarone, Massimo
Cabibbo, Giuseppe
Montes, Margarida
Foschi, Francesco Giuseppe
Vivaldi, Caterina
Solda, Caterina
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Hiraoka, Atsushi
LIVER CANCER, 2024, 13 (05) : 522 - 536
[4] Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Ben Khaled, Najib
Moeller, Marie
Jochheim, Leonie S.
Leyh, Catherine
Ehmer, Ursula
Boettcher, Katrin
Pinter, Matthias
Balcar, Lorenz
Scheiner, Bernhard
Weich, Alexander
Leicht, Hans Benno
Zarka, Valentina
Ye, Liangtao
Schneider, Julia
Piseddu, Ignazio
Oecal, Osman
Rau, Monika
Sinner, Friedrich
Venerito, Marino
Gairing, Simon Johannes
Foerster, Friedrich
Mayerle, Julia
Toni, Enrico N. De
Geier, Andreas
Reiter, Florian P.
JHEP REPORTS, 2024, 6 (06)
[5] Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Zhang, Hui
Shao, Minghua
Tan, Binbin
Fu, Yin
Yuan
Chen, Hailei
CANCER RESEARCH, 2024, 84 (06)
[6] Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
de Castro, Tiago
Welland, Sabrina
Jochheim, Leonie
Leyh, Cathrine
Shmanko, Kateryna
Finkelmeier, Fabian
Jeliazkova, Petia
Jefremow, Andre
Gonzalez-Carmona, Maria A.
Kandulski, Arne
Roessler, Daniel
Ben Khaled, Najib
Enssle, Stefan
Venerito, Marino
Fruendt, Thorben W.
Schultheiss, Michael
Djanani, Angela
Pangerl, Maria
Maieron, Andreas
Wirth, Thomas C.
Marquardt, Jens U.
Greil, Richard
Fricke, Christina
Guenther, Rainer
Schmiderer, Andreas
Bettinger, Dominik
Wege, Henning
Scheiner, Bernhard
Mueller, Martina
Strassburg, Christian P.
Siebler, Juergen
Ehmer, Ursula
Waidmann, Oliver
Weinmann, Arndt
Pinter, Matthias
Lange, Christian M.
Saborowski, Anna
Vogel, Arndt
HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
[7] Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings
Ohama, Hideko
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kosaka, Hisashi
Matono, Tomomitsu
Shibata, Hiroshi
Aoki, Tomoko
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Iijima, Hiroko
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
Kumada, Takashi
ONCOLOGY, 2023, 101 (09) : 542 - 552
[8] INITIAL EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE
Iwamoto, Hideki
Shimose, Shigeo
Takashi, Niizeki
Noda, Yu
Shirono, Tomotake
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
HEPATOLOGY, 2021, 74 : 652A - 652A
[9] Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Iwamoto, Hideki
Shimose, Shigeo
Noda, Yu
Shirono, Tomotake
Niizeki, Takashi
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Sakai, Miwa
Kajiwara, Akira
Itano, Satoshi
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
CANCERS, 2021, 13 (11)
[10] Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma
Ha, Yeonjung
Cheon, Jaekyung
Hwang, Seong Gyu
Chon, Hong Jae
JOURNAL OF HEPATOLOGY, 2021, 75 : S526 - S527

← 1 2 3 4 5 →